Inloggen
E-mail
Wachtwoord
Paswoord weergeven
Bewaren
Bent u uw wachtwoord vergeten?
Gratis lid worden
Registreer
Registreer
Instellingen
Instellingen
Dynamische koersen 
OFFON
  1. Homepagina
  2. Aandelen
  3. BelgiŽ
  4. Euronext Bruxelles
  5. Argenx SE
  6. Nieuws
  7. Persberichten
    ARGX   NL0010832176

ARGENX SE

(ARGX)
Real-time koersen. Real Time Euronext Bruxelles - 02/12 17:35:27
257.3 EUR   +2.96%
10:08Kepler Cheuvreux zet Argen-x op kooplijst
AM
29/11Europese ADR's bewegen lichtjes hoger in de maandaghandel
MT
29/11ARGENX SE : Piper Sandler zet aandeel op kooplijst
MM
OverzichtKoersenGrafiekenNieuwsRatingsAgendaOndernemingFinanciŽnConsensusHerzieningenBeursproducten 
OverzichtAl het nieuwsAanbevelingen van analistenAndere talenPersberichtenOfficiŽle publicatiesSectornieuwsAnalyse MarketScreener
Communiquťs de presse de la sociťtť ARGENX SE
10/11Argenx SE, - argenx to Present at Upcoming Investor Conferences
PU
10/11Argenx to Present at Upcoming Investor Conferences
AQ
28/10Argenx SE, - argenx Reports Third Quarter 2021 Financial Results and Provides Business ..
PU
28/10Argenx Reports Third Quarter 2021 Financial Results and Provides Business Update
AQ
21/10ARGENX : argenx to Report Third Quarter 2021 Financial Results and Business Update on Octo..
PU
21/10ARGENX : to Report Third Quarter 2021 Financial Results and Business Update on October 28,..
AQ
08/10ARGENX : argenx to Highlight Potential First-in-Class FcRn Antagonist Efgartigimod at Upco..
PU
08/10argenx to Highlight Potential First-in-Class FcRn Antagonist Efgartigimod at Upcoming N..
GL
08/10ARGENX : to Highlight Potential First-in-Class FcRn Antagonist Efgartigimod at Upcoming Ne..
GL
03/09ARGENX : to Present at Upcoming Investor Conferences
AQ
02/09ARGENX : to Present at Upcoming Investor Conferences
PU
25/08ARGENX : Announces Validation of European Marketing Authorization Application for Efgartig..
AQ
04/08ARGENX : argenx to Present at 2021 Wedbush PacGrow Virtual Healthcare Conference
PU
04/08ARGENX : to Present at 2021 Wedbush PacGrow Virtual Healthcare Conference
AQ
30/07ARGENX : Halfjaarlijkse Financiële verslaggeving
PU
29/07ARGENX : argenx Reports Half Year 2021 Financial Results and Provides Second Quarter Busin..
PU
29/07ARGENX : Reports Half Year 2021 Financial Results and Provides Second Quarter Business Upd..
AQ
22/07ARGENX : argenx to Report Half Year 2021 Financial Results and Second Quarter Business Upd..
PU
22/07argenx to Report Half Year 2021 Financial Results and Second Quarter Business Update on..
GL
22/07ARGENX : to Report Half Year 2021 Financial Results and Second Quarter Business Update on ..
AQ
14/07ARGENX : argenx to Host Virtual R&D Day on July 20, 2021
PU
14/07ARGENX : to Host Virtual R&D Day on July 20, 2021
AQ
17/06argenx announces publication of Phase 3 ADAPT trial results of efgartigimod for the tre..
GL
07/06ARGENX : to regain global rights to cusatuzumab (Form 6-K)
PU
07/06argenx to regain global rights to cusatuzumab
GL
01/06ARGENX : Appoints Karl Gubitz as Chief Financial Officer (Form 6-K)
PU
01/06argenx Appoints Karl Gubitz as Chief Financial Officer
GL
01/06ARGENX : to Present at Upcoming Investor Conferences
AQ
14/05argenx Reports First Quarter 2021 Financial Results and Provides Business Update
GL
11/05argenx announces results of Annual General Meeting of Shareholders
GL
11/05ARGENX : announces results of Annual General Meeting of Shareholders (Form 6-K)
PU
07/05argenx to Report First Quarter 2021 Financial Results and Business Update on May 14, 20..
GL
28/04argenx Management to Present at Upcoming Virtual Investor Conferences
GL
30/03argenx announces Annual General Meeting of Shareholders on May 11, 2021
GL
04/03argenx Reports Full Year 2020 Financial Results and Provides Fourth Quarter Business Up..
GL
02/03argenx Announces FDA Acceptance of BLA Filing for Efgartigimod for the Treatment of Gen..
GL
25/02ARGENX : to Report Full Year 2020 Financial Results and Fourth Quarter Business Update on ..
AQ
08/02BROADRIDGE FINANCIAL : argenx announces closing of global offering
AQ
05/02argenx announces closing of global offering
GL
05/02ARGENX : announces full exercise of underwriters option to purchase additional ADSs
AQ
04/02argenx announces full exercise of underwriters' option to purchase additional ADSs
GL
03/02argenx raises $1.0 billion in gross proceeds in a global offering
GL
02/02ARGENX : Issues Statement Concerning Efgartigimod
AQ
02/02argenx Issues Statement Concerning Efgartigimod
GL
01/02argenx announces launch of proposed global offering
GL
01/02“GO” DECISION : ADHERE Trial in CIDP
PU
01/02argenx Announces “GO” Decision in ADHERE Trial of Efgartigimod in Chronic I..
GL
08/01ARGENX : Announces 2021 Corporate Priorities and Highlights Recent Achievements Across Imm..
AQ
05/01ARGENX : to Present at 39th Annual J.P. Morgan Healthcare Conference
AQ
04/01argenx to Present at 39th Annual J.P. Morgan Healthcare Conference
GL
2020ARGENX : Enters Into Agreement To Acquire Priority Review Voucher
AQ
2020argenx Enters Into Agreement To Acquire Priority Review Voucher
GL
2020ARGENX : to Participate in Upcoming Virtual Investor Conferences
AQ
2020argenx to Participate in Upcoming Virtual Investor Conferences
GL
2020ARGENX : Q3 FY20 Earnings conference call and audio webcast
PU
2020ARGENX : Reports Third Quarter 2020 Financial Results and Provides Business Update
AQ
2020argenx Reports Third Quarter 2020 Financial Results and Provides Business Update
GL
2020ARGENX : to Report Third Quarter 2020 Financial Results and Business Update on October 22,..
AQ
2020ARGENX : to Report Third Quarter 2020 Financial Results and Business Update on October 22,..
AQ
2020argenx to Report Third Quarter 2020 Financial Results and Business Update on October 22..
GL
2020ARGENX : Expands Capabilities In Antibody Engineering Through Key Technology Partnerships
AQ
2020argenx Expands Capabilities In Antibody Engineering Through Key Technology Partnerships
GL
2020ARGENX : Presents Additional Efgartigimod Data from Global Phase 3 ADAPT Trial at the Myas..
AQ
2020argenx Presents Additional Efgartigimod Data from Global Phase 3 ADAPT Trial at the Mya..
GL
2020ARGENX : MGFA 2020 Virtual Scientific Session
PU
2020argenx Management to Present at Upcoming Virtual Investor Conferences
GL
2020argenx to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference
GL
2020ARGENX : Half year 2020 financial results and second quarter business update on July 30, 2..
PU
2020argenx reports half year 2020 financial results and provides second quarter business up..
GL
2020ARGENX : Announces Positive Topline Phase 3 ADAPT Trial Results
PU
2020ARGENX : Positive Topline Phase 3 ADAPT Trial Results
PU
2020ARGENX : Securities Note
PU
2020argenx announces closing of global offering
GL
2020argenx announces full exercise of underwriters' option to purchase additional ADSs
GL
2020argenx raises $750 million in gross proceeds in a global offering
GL
1  2  3  4  5Volgende